You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

BRICANYL Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Bricanyl, and when can generic versions of Bricanyl launch?

Bricanyl is a drug marketed by Sanofi Aventis Us and is included in three NDAs.

The generic ingredient in BRICANYL is terbutaline sulfate. There are seven drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the terbutaline sulfate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Bricanyl

A generic version of BRICANYL was approved as terbutaline sulfate by IMPAX LABS on June 26th, 2001.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for BRICANYL?
  • What are the global sales for BRICANYL?
  • What is Average Wholesale Price for BRICANYL?
Summary for BRICANYL
Drug patent expirations by year for BRICANYL
Recent Clinical Trials for BRICANYL

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of MonastirPhase 1
Yaakov BeilinPhase 2/Phase 3
University of MonastirPhase 3

See all BRICANYL clinical trials

US Patents and Regulatory Information for BRICANYL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us BRICANYL terbutaline sulfate AEROSOL, METERED;INHALATION 018000-001 Mar 19, 1985 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us BRICANYL terbutaline sulfate TABLET;ORAL 017618-002 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us BRICANYL terbutaline sulfate INJECTABLE;INJECTION 017466-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us BRICANYL terbutaline sulfate TABLET;ORAL 017618-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for BRICANYL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi Aventis Us BRICANYL terbutaline sulfate INJECTABLE;INJECTION 017466-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us BRICANYL terbutaline sulfate AEROSOL, METERED;INHALATION 018000-001 Mar 19, 1985 ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us BRICANYL terbutaline sulfate TABLET;ORAL 017618-002 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us BRICANYL terbutaline sulfate INJECTABLE;INJECTION 017466-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us BRICANYL terbutaline sulfate TABLET;ORAL 017618-001 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us BRICANYL terbutaline sulfate AEROSOL, METERED;INHALATION 018000-001 Mar 19, 1985 ⤷  Sign Up ⤷  Sign Up
Sanofi Aventis Us BRICANYL terbutaline sulfate TABLET;ORAL 017618-002 Approved Prior to Jan 1, 1982 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for BRICANYL

See the table below for patents covering BRICANYL around the world.

Country Patent Number Title Estimated Expiration
Denmark 128491 ⤷  Sign Up
Finland 54798 ⤷  Sign Up
Italy 8048168 ⤷  Sign Up
Spain 361429 ⤷  Sign Up
Netherlands 7513854 ⤷  Sign Up
Switzerland 512428 Verfahren zur Herstellung von neuen 1-(3',5'-Dihydroxy- bzw. -acyloxy-phenyl)-2-aminoäthanolen und deren physiologisch verträglichen Säureadditionssalzen ⤷  Sign Up
Spain 361433 ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.